iRadimed Corporation (IRMD) is a publicly traded Healthcare sector company. As of May 21, 2026, IRMD trades at $90.40 with a market cap of $1.13B and a P/E ratio of 47.84. IRMD moved +1.82% today. Year to date, IRMD is -8.04%; over the trailing twelve months it is +69.64%. Its 52-week range spans $46.86 to $107.90. Analyst consensus is buy with an average price target of $116.00. Rallies surfaces IRMD's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
What changed in IRMD news today?
iRadimed Q1 Revenue Jumps 13% to $22M; 3,870 Pump ASPs Rise 20%: iRadimed Corp reported Q1 revenue growth of 13% to $22 million and net income rising 22% to $5.8 million. Initial orders for the new 3,870 MR IV pump system show a 20% ASP increase, but Q2 guidance is set at $20–21 million due to production constraints.
iRadimed Q1 Revenue Jumps 13% to $22M; 3,870 Pump ASPs Rise 20%: iRadimed Corp reported Q1 revenue growth of 13% to $22 million and net income rising 22% to $5.8 million. Initial orders for the new 3,870 MR IV pump system show a 20% ASP increase, but Q2 guidance is set at $20–21 million due to production constraints.
Does Rallies summarize IRMD news?
Yes. Rallies summarizes IRMD news with ticker-specific context, catalysts, source links, and AI-generated market summaries when news is available.
Is IRMD research on Rallies investment advice?
No. Rallies provides research, data, and educational context for IRMD. It does not provide personalized investment advice.
